X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
canakinumab (ACZ885/Ilaris), is a human monoclonal antibody that binds with high affinity and selectivity to human IL-1β and inhibits IL-1β activity by blocking its interaction with its receptors.
Lead Product(s): Canakinumab
Therapeutic Area: Oncology Product Name: Ilaris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to human interleukin-1beta (IL-1β) and neutralizes IL-1β activity by blocking its interaction with its receptors.
Lead Product(s): Canakinumab,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: ACZ885
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
LNA043 is a ANGPTL3 agonist that targets damaged cartilage and modulates several pathways involved in cartilage regeneration. LNA043 resulted in regeneration of damaged cartilage in patients with femoral articular cartilage lesions in a proof of concept study.
Lead Product(s): LNA043,Canakinumab
Therapeutic Area: Musculoskeletal Product Name: LNA043
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
This new indication follows the existing approval of Ilaris for Systemic Juvenile Idiopathic Arthritis (SJIA)1, now allowing patients over the age of 16 to be treated. Ilaris is an interleukin-1 beta inhibitor that provides a new mode of treatment for this disease.
Lead Product(s): Canakinumab
Therapeutic Area: Rare Diseases and Disorders Product Name: Ilaris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
Novartis announced that the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS).
Lead Product(s): Canakinumab,Docetaxel
Therapeutic Area: Oncology Product Name: ACZ885
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
The Phase III trial investigating canakinumab plus standard of care did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC.
Lead Product(s): Canakinumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Ilaris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
In a study of Ilaris in 10,000 patients with a history of heart attack it is found that people taking the drug had 40% to 47% lower rates of total knee or hip replacements than did those taking a placebo.
Lead Product(s): Canakinumab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ilaris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
The U.S. Food and Drug Administration approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD).
Lead Product(s): Canakinumab
Therapeutic Area: Rare Diseases and Disorders Product Name: Ilaris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The CAN-COVID trial will examine the efficacy of utilizing canakinumab, to treat a type of severe immune overreaction called cytokine release syndrome in people with COVID-19 pneumonia.
Lead Product(s): Canakinumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
